Oncocyte appoints independent director John Peter Gutfreund; he and fund invest $10.5M

Insight Molecular Diagnostics Inc.

John Peter Gutfreund elected independent director effective July 28, 2022; to chair Finance Committee.
Gutfreund invested $1M in Series A Preferred Stock (1,176.48 shares) in April 2022 registered direct offering.
Halle Special Situations Fund LLC, affiliated with Gutfreund, purchased ~$9.5M in common stock and warrants in April 2022.
CEO expects to bring three major products through reimbursement and to market over next four quarters.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John Peter Gutfreund

Director

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2022-07-28
Filed: August 1, 2022, 7:59 PM ET

Effective July 28, 2022, the Board of Directors (the “Board”) of Oncocyte Corporation (“Oncocyte” or the “Company”) elected John Peter Gutfreund, age 36, to serve as a director on the Board, with a term that expires at the Annual Meeting of Shareholders of the Company to be held in 2023 or until his earlier resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Peter Gutfreund was elected as Director at Insight Molecular Diagnostics Inc..

Action: elected
Role: Director

Exact text from the filing

Effective July 28, 2022, the Board of Directors (the “Board”) of Oncocyte Corporation (“Oncocyte” or the “Company”) elected John Peter Gutfreund, age 36, to serve as a director on the Board, with a term that expires at the Annual Meeting of Shareholders of the Company to be held in 2023 or until his earlier resignation or removal.

View on SEC.gov

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-020809

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.